| Protein Name |
NRF2 |
| Gene |
NFE2L2 |
| UniProt |
Q16236 |
| PDB |
2FLU, 3WN7 |
| Molecular Weight |
~68 kDa (605 amino acids) |
| Subcellular Localization |
Cytoplasm → Nucleus (upon activation) |
| Protein Family |
Cap'n'Collar (CNC) bZIP transcription factor |
Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NRF2 (Nuclear factor erythroid 2-related factor 2), encoded by the NFE2L2 gene on chromosome 2q31.2, is the master transcriptional regulator of the cellular antioxidant and cytoprotective response. NRF2 orchestrates the expression of over 250 genes containing antioxidant response elements (AREs) in their promoters, encoding a broad battery of phase II detoxification enzymes, antioxidant proteins, and anti-inflammatory mediators [1][2]. Under basal conditions, NRF2 is kept at low levels through ubiquitin-proteasome degradation mediated by its negative regulator Keap1 (Kelch-like ECH-associated protein 1). Upon [oxidative stress[/mechanisms/oxidative-stress, electrophilic signals, or therapeutic activators, NRF2 dissociates from Keap1, translocates to the nucleus, and drives transcription of cytoprotective genes [1].
NRF2 dysfunction has been implicated in virtually all major neurodegenerative diseases, including [Alzheimer's disease[/diseases/alzheimers, [Parkinson's disease[/diseases/parkinsons, [ALS[/diseases/als, [Huntington's disease[/mechanisms/huntington-pathway, and [multiple sclerosis[/diseases/multiple-sclerosis. In these conditions, NRF2 activity declines with aging and disease
progression, leaving [neurons[/entities/neurons and glia increasingly vulnerable to [oxidative stress[/mechanisms/oxidative-stress, [mitochondrial dysfunction[/mechanisms/mitochondrial-dysfunction, and [neuroinflammation[/mechanisms/neuroinflammation
[2][3]. Pharmacological NRF2 activators — including dimethyl fumarate (Tecfidera), already FDA-approved for MS — represent
one of the most promising therapeutic strategies for neuroprotection across multiple neurodegenerative diseases [1][3].
NRF2 is a 605-amino-acid Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor with seven functional Neh (Nrf2-ECH homology) domains:
- Neh1: Contains the CNC-bZIP domain for DNA binding and dimerization with small Maf proteins; mediates binding to ARE sequences (5′-TGACnnnGC-3′) in target gene promoters [1].
- Neh2: N-terminal regulatory domain containing DLG and ETGE motifs that interact with Keap1 for ubiquitin-dependent degradation. The "hinge and latch" model describes how the high-affinity ETGE and low-affinity DLG motifs bind Keap1 [1].
- Neh3: C-terminal transactivation domain; interacts with the chromo-ATPase/helicase DNA-binding domain (CHD6).
- Neh4 and Neh5: Transactivation domains that recruit CBP/p300 coactivators.
- Neh6: Serine-rich domain; mediates Keap1-independent degradation through β-TrCP/[GSK-3β[/entities/gsk3-beta phosphorylation.
- Neh7: Interacts with retinoic X receptor α (RXRα) to repress NRF2 activity.
The canonical NRF2 activation pathway operates as a cellular stress sensor [1][2]:
- Basal state: Keap1 homodimer binds NRF2 via the DLG and ETGE motifs, serving as a substrate adapter for the Cul3-RING ubiquitin E3 ligase complex. NRF2 is continuously ubiquitinated and degraded by the [ubiquitin-proteasome system[/entities/ubiquitin-proteasome-system, maintaining low basal levels (half-life ~20 minutes).
- Stress activation: Oxidative or electrophilic stress modifies reactive cysteine residues in Keap1 (especially Cys151, Cys273, Cys288), disrupting the Keap1-NRF2 interaction. NRF2 escapes degradation, accumulates, and translocates to the nucleus [1].
- Transcriptional activation: Nuclear NRF2 heterodimerizes with small Maf proteins and binds to ARE sequences in target gene promoters, activating transcription of cytoprotective genes.
- Resolution: Once stress is resolved, Keap1 shuttles to the nucleus to retrieve NRF2 and restore basal activity levels.
NRF2 drives expression of a comprehensive cytoprotective program [2][4]:
| Category |
Target Genes |
Function |
| Antioxidant enzymes |
HO-1, NQO1, SOD, catalase, GPx |
Neutralize reactive oxygen species |
| Glutathione synthesis |
GCLC, GCLM, GSS, GSR |
Rate-limiting enzymes for glutathione biosynthesis |
| Thioredoxin system |
TXN, TXNRD1 |
Reduce oxidized proteins |
| Phase II detoxification |
GSTs, UGTs |
Conjugate and detoxify xenobiotics |
| Proteasome subunits |
PSMB5, PSMA1 |
Enhance [protein quality control] |
| Anti-inflammatory |
IL-1β suppression, HMOX1 |
Reduce [neuroinflammation[/mechanisms/neuroinflammation |
| Iron metabolism |
Ferritin H/L, ferroportin |
Prevent [ferroptosis[/mechanisms/ferroptosis |
| Mitophagy |
PINK1, p62/SQSTM1 |
Promote [mitophagy[/mechanisms/mitophagy of damaged mitochondria |
NRF2 activity is reduced in the [hippocampus[/brain-regions/hippocampus and [cortex[/brain-regions/cortex of AD patients, with nuclear NRF2 levels decreasing as disease severity increases
[2][3]:
- [Amyloid-Beta[/proteins/Amyloid-Beta oligomers generate [oxidative stress[/mechanisms/oxidative-stress that initially activates NRF2, but chronic exposure overwhelms the pathway, leading to NRF2 exhaustion
- Hyperphosphorylated tau[/proteins/tau-protein disrupts NRF2 nuclear import, further compromising antioxidant defenses [3]
- NRF2 knockout mice show exacerbated amyloid pathology, [neuroinflammation[/mechanisms/neuroinflammation, and cognitive deficits
- NRF2 activation (by sulforaphane, DMF, or genetic overexpression) ameliorates AD pathology in transgenic mouse models [2][1]
- Loss of [dopaminergic neurons[/cell-types/dopaminergic-neurons-snpc in the [substantia nigra[/brain-regions/substantia-nigra is associated with high oxidative burden and diminished NRF2 signaling [2]
- [alpha-synuclein[/proteins/alpha-synuclein aggregates impair NRF2 function by sequestering p62/SQSTM1, disrupting selective autophagy [2]
- NRF2 activators protect dopaminergic [neurons[/entities/neurons in MPTP, 6-OHDA, and rotenone PD models [1]
- [PINK1[/proteins/pink1-protein and [Parkin[/proteins/parkin-mediated [mitophagy[/mechanisms/mitophagy is positively regulated by NRF2 through p62 induction
- [SOD1[/proteins/sod1-protein mutant mice show progressive decline in NRF2 activity in spinal cord [motor neurons[/cell-types/motor-neurons
- NRF2 activation delays disease onset and extends survival in SOD1-G93A mice [1]
- [TDP-43[/proteins/tdp-43 proteinopathy impairs NRF2-mediated stress response in motor [neurons[/entities/neurons
- Mutant [huntingtin[/proteins/huntingtin protein disrupts NRF2-dependent gene expression in striatal [medium spiny neurons[/cell-types/medium-spiny-neurons
- NRF2 activation reduces mutant [huntingtin[/proteins/huntingtin aggregation and improves motor function in HD models [2]
NRF2 activation is a highly active area of therapeutic development for neurodegeneration [1][3]:
- Dimethyl fumarate (DMF / Tecfidera): FDA-approved for [multiple sclerosis[/diseases/multiple-sclerosis. Activates NRF2 by modifying Keap1 cysteine residues. Reduces neuroinflammation, enhances glutathione levels, and protects oligodendrocytes. Under investigation for AD and PD [1][3].
- Omaveloxolone (Skyclarys): FDA-approved for [Friedreich's Ataxia[/diseases/friedreichs-ataxia (2023). The first NRF2 activator approved specifically for a neurodegenerative condition. Synthetic triterpenoid that potently activates NRF2 [3].
- Sulforaphane: Natural isothiocyanate from cruciferous vegetables; potent NRF2 activator; clinical trials in autism, AD, and schizophrenia
- Curcumin analogs: Modified curcuminoids with improved bioavailability; NRF2 activators in preclinical studies
- CDDO derivatives: Synthetic triterpenoids with NRF2-activating properties; clinical trials for various indications
The study of Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [NRF2 as a Therapeutic Target in Neurodegenerative Diseases]https://doi.org/10.1177/1759091419899782). ASN Neuro, 2020.
- [Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer's Disease]https://doi.org/10.3390/antiox10071069). Antioxidants, 2021.
- [Reinforcing Nrf2 Signaling: Help in the Alzheimer's Disease Context]https://doi.org/10.3390/ijms26031130). International Journal of Molecular Sciences, 2025.
- [Targeting the NRF2 pathway for disease modification in neurodegenerative diseases]https://doi.org/10.3389/fphar.2024.1437939). Frontiers in Pharmacology, 2024.
- [Chen J, et al. Nrf2 pathways in neuroprotection: Alleviating mitochondrial dysfunction and cognitive impairment in aging. Life Sciences, 2024;357:122950. . DOI
- [Cuadrado A, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nature Reviews Drug Discovery, 2019;18(4):295-317. . DOI
- [Pajares M, et al. Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. [Autophagy[/entities/autophagy, 2016;12(10):1902-1916. . DOI
- [Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radical Biology and Medicine, 2015;88(Pt B]:179-188. . DOI
- UniProt: Q16236https://www.uniprot.org/uniprot/Q16236
-
-
-
-
-
-
-
-
-
- [HSP70 (Heat Shock Protein 70 / HSPA1A)[/proteins/hsp70
-
-
-
-
- [SOD1 (Cu/Zn Superoxide Dismutase)[/proteins/sod1-protein## External Links
-
-
- PDB: 2FLU (Neh2-Keap1 complex), 3WN7 (bZIP-ARE complex)
-